Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Recent Advancements in Nanobiotechnology and Immunotherapy for the Treatment of...
share announcement

Recent Advancements in Nanobiotechnology and Immunotherapy for the Treatment of Solid Tumors

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".

Deadline for manuscript submissions: closed (20 August 2023) | Viewed by 4488

Special Issue Editors

Dr. Francesco Mainini

E-Mail Website
Guest Editor
Nanomedicine Laboratory, Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, via G.B. Grassi, 74 20157 Milan, Italy
Interests: nanoparticles; immunotherapy; tumor immunology; targeted therapy
Dr. Ovidio Catanzano

E-Mail Website
Guest Editor
National Research Council - Institute for Polymers, Composites and Biomaterials (IPCB-CNR), via Campi Flegrei 34, 80078 Pozzuoli, Italy
Interests: drug delivery; nanotechnologies; polymer therapeutics; skin delivery; biomaterials for tissue engineering
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Onco-immunotherapies, such as immune checkpoint blockade inhibitors and adoptive cell therapies, are revolutionizing the field of cancer therapy due to their ability to induce strong anti-tumor immune responses. Many novel immune-based cancer therapies are rapidly moving from the bench to the clinic. However, despite being very effective in hematological and some solid tumors, unresponsiveness, development of therapy resistance, and serious adverse effects limit their capacity to impact the vast majority of solid tumors. The use of nanoparticle-based delivery systems (NPs) to improve conventional onco-immunotherapies is gaining traction due largely to the versatility of this approach; these systems can be loaded with a wide variety of molecular cargoes and finely tuned to release their contents into the tumor microenvironment. NPs can be engineered to deliver combinations of adjuvants and antigens, as in the case of nanovaccines. This Special Issue aims to collect manuscripts related to the development of novel nanotherapeutics to remodel the tumor microenvironment and enhance immunotherapies for the treatment of solid tumors.

We are inviting the submission of high-quality research papers and reviews exploring the synergistic combinations between nanotherapeutics and immunomodulatory molecules for the treatment of solid tumors. We expect to receive contributions from different areas of multidisciplinary research, including (but not restricted to): innovative immunomodulatory nanomaterial design, NP surface functionalization and characterization, the relationship between the physicochemical properties of NPs and their immunomodulation properties, and potential new therapeutic applications in solid tumor treatment. This Special Issue aims to make a significant collective contribution to this field of study and facilitate the development of new therapeutic approaches for cancer patients.

We look forward to receiving your contributions.

Dr. Francesco Mainini
Dr. Ovidio Catanzano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanobiotechnology
  • nanoparticles
  • immunotherapy
  • cancer
  • solid tumors
  • nanotechnology
  • nanomedicine
  • adoptive cell therapy
  • nanovaccines
  • immunomodulation
  • tumor microenvironment
  • immune checkpoint
  • PD-1

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 2493 KiB  
Article
Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment–Drug Conjugates (FDCs)
by Louis Jolivet, Imène Ait Mohamed Amar, Catherine Horiot, Fanny Boursin, Cyril Colas, Stéphanie Letast, Caroline Denevault-Sabourin, Emilie Allard-Vannier, Nicolas Joubert and Nicolas Aubrey
Pharmaceutics 2022, 14(8), 1524; https://doi.org/10.3390/pharmaceutics14081524 - 22 Jul 2022
Cited by 4 | Viewed by 1662
Abstract
Antibody–drug conjugates (ADCs) derived from a full immunoglobulin-G (IgG) are associated with suboptimal solid-tumor penetration and Fc-mediated toxicities. Antibody fragment–drug conjugates (FDCs) could be an alternative. Nevertheless, innovative solutions are needed to implant cysteines as conjugation sites in the single-chain fragment variable (scFv) [...] Read more.
Antibody–drug conjugates (ADCs) derived from a full immunoglobulin-G (IgG) are associated with suboptimal solid-tumor penetration and Fc-mediated toxicities. Antibody fragment–drug conjugates (FDCs) could be an alternative. Nevertheless, innovative solutions are needed to implant cysteines as conjugation sites in the single-chain fragment variable (scFv) format, which is the backbone from which many other antibody formats are built. In addition, the bioconjugation site has the utmost importance to optimize the safety and efficacy of bioconjugates. Our previous intra-tag cysteine (ITC) strategy consisted of introducing a bioconjugation motif at the C-terminal position of the 4D5.2 scFv, but this motif was subjected to proteolysis when the scFv was produced in CHO cells. Considering these data, using three intra-domain cysteine (IDC) strategies, several parameters were studied to assess the impact of different locations of a site-specific bioconjugation motif in the variable domains of an anti-HER2 scFv. In comparison to the ITC strategy, our new IDC strategy allowed us to identify new fragment–drug conjugates (FDCs) devoid of proteolysis and exhibiting enhanced stability profiles, better affinity, and better ability to kill selectively HER2-positive SK-BR-3 cells in vitro at picomolar concentrations. Thus, this work represents an important optimization step in the design of more complex and effective conjugates. Full article
(This article belongs to the Special Issue Recent Advancements in Nanobiotechnology and Immunotherapy for the Treatment of Solid Tumors)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

21 pages, 677 KiB  
Review
Nanomedicine for Combination Urologic Cancer Immunotherapy
by Yun Tian, Zhenzhu Liu, Jianbo Wang, Linan Li, Fuli Wang, Zheng Zhu and Xuejian Wang
Pharmaceutics 2023, 15(2), 546; https://doi.org/10.3390/pharmaceutics15020546 - 06 Feb 2023
Cited by 4 | Viewed by 2255
Abstract
Urologic cancers, particularly kidney, bladder, and prostate cancer, have a growing incidence and account for about a million annual deaths worldwide. Treatments, including surgery, chemotherapy, radiotherapy, hormone therapy, and immunotherapy are the main therapeutic options in urologic cancers. Immunotherapy is now a clinical [...] Read more.
Urologic cancers, particularly kidney, bladder, and prostate cancer, have a growing incidence and account for about a million annual deaths worldwide. Treatments, including surgery, chemotherapy, radiotherapy, hormone therapy, and immunotherapy are the main therapeutic options in urologic cancers. Immunotherapy is now a clinical reality with marked success in solid tumors. Immunological checkpoint blockade, non-specific activation of the immune system, adoptive cell therapy, and tumor vaccine are the main modalities of immunotherapy. Immunotherapy has long been used to treat urologic cancers; however, dose-limiting toxicities and low response rates remain major challenges in the clinic. Herein, nanomaterial-based platforms are utilized as the “savior”. The combination of nanotechnology with immunotherapy can achieve precision medicine, enhance efficacy, and reduce toxicities. In this review, we highlight the principles of cancer immunotherapy in urology. Meanwhile, we summarize the nano-immune technology and platforms currently used for urologic cancer treatment. The ultimate goal is to help in the rational design of strategies for nanomedicine-based immunotherapy in urologic cancer. Full article
(This article belongs to the Special Issue Recent Advancements in Nanobiotechnology and Immunotherapy for the Treatment of Solid Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop